Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody

Leukemia

Volumn 10, Issue 11, 1996, Pages 1765-1772

  Csoka M ^a,b   Strauss G ^a   Debatin, K M ^b,c   Moldenhauer, G ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

B lineage ALL; Bispecific monoclonal antibody; Directed T cell cytotoxicity; Immunotherapy; T lymphocyte activation;

Indexed keywords

BISPECIFIC ANTIBODY; CD19 ANTIGEN; CD3 ANTIGEN; CD3XCD19 BISPECIFIC ANTIBODY; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BLAST CELL; CANCER IMMUNOTHERAPY; CELL FUSION; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG EFFECT; HUMAN; HUMAN CELL; HYBRIDOMA; IMMUNOREACTIVITY; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 10344264950     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Ludwig WD, Reiter A, Löffler H, Gokbuget A, Hölzer D, Riehm H, Thiel E. Immunophenotypic features of childhood and adult acute lymphoblastic leukemia (ALL): experience of the German Multicentre Trials ALL-BFM and GMALL. Leuk Lymphoma 1994; 13 (Suppl. 1): 71-76.
2. Foon KA. Biological response modifers: the new immunotherapy. Cancer Res 1989; 49: 1621-1639.
3. Chapman PB, Houghton AN. Non-antibody immunotherapy of cancer. Curr Opin Immunol 1993; 5: 726-731.
4. Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 1992; 80: 863-878.
5. Riethmüller G, Schneider-Gädicke E, Johnson JP. Monoclonal antibodies in cancer therapy. Curr Opin Immunol 1993; 5: 732-739.
6. Vitetta ES, Thorpe PE, Uhr JW. Immunotoxins: magic bullets or misguided missiles. Immunol Today 1993; 14: 252-259.
7. Vallera DA. Immunotoxins: will their clinical promise be fulfilled? Blood 1994; 83: 309-317.
8. Goldenberg DM, Horowitz JA, Sharkey RM, Hall TC, Murthy S, Goldenberg H, Lee RE, Stein R, Siegel JA, Izon DO, Burger K, Swayne LC, Belisle E, Hansen HJ, Pinsky CM. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 1991; 9: 548-564.
9. 131I-B1 (anti CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346: 336-340.
10. Ortaldo JR, Woodhouse C, Morgan AC, Herberman RB, Cheresh DA, Reisfeld R. Analysis of effector cells in human antibody-dependent cellular cytotoxicity with murine monoclonal antibodies. J Immunol 1987; 138: 3566-3572.
11. Hellström I, Garrigues U, Lavie E, Hellström KE. Antibody-mediated killing of human tumor cells by attached effector cells. Cancer Res 1988; 48: 624-627.
12. Herlyn DM, Koprowski H. Monoclonal anticolon carcinoma antibodies in complement-dependent cytotoxicity. Int J Cancer 1981; 27: 769-774.
13. Jung G, Müller Eberhard HJ. An in vitro model for tumor immunotherapy with antibody heteroconjugates. Immunol Today 1988; 9: 257-260.
14. Nolan O, O'Kennedy R. Bifunctional antibodies and their potential clinical applications. Int J Clin Lab Res 1992; 22: 21-27.
15. Ring DB, Hsieh-Ma ST, Shi T, Reeder J. Antigen forks: bispecific reagents that inhibit cell growth by binding selected pairs of tumor antigens. Cancer Immunol Immunother 1994; 39: 41-48.
16. Nitta T, Sato K, Yagita H, Okumura K, Ishii S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet 1990; 335: 368-371.
17. Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, DiRe E, Eggermont AMM, Goey SH, Gratama JW, Lamers CHJ, Nooy MA, Parmiani G, Raspagliesi F, Ravagnani F, Scarfone G, Trimbos JB, Warnaar SO, Bolhuis RLH. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 1995; 87: 1463-1469.
18. De Gast GC, Haagen IA, van Houten AA, Klein SC, Duits AJ, de Weger RA, Vroom TM, Clark M, Philips J, van Dijk AJG, de Lau WBM, Bast BJ. CD8 T cell activation after intravenous administration of CD3×CD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol Immunother 1995; 40: 390-396.
19. Cook AG, Wood PJ. Chemical synthesis of bispecific monoclonal antibodies: potential advantages in immunoassay systems. J Immunol Meth 1994; 171: 227-237.
20. Milstein C, Cuello AC. Hybrid hybridomas and the production of bi-specific monoclonal antibodies. Immunol Today 1984; 5: 299-304.
21. Bolhuis RLH, Sturm E, Braakman E. T cell targeting in cancer therapy. Cancer Immunol Immunother 1991; 34: 1-8.
22. Weidmann E, Trucco M, Whiteside TL. Relevance of the T cell receptor for immunotherapy of cancer. Cancer Immunol Immunother 1994; 39: 1-14.
23. Weiner GJ, Kostelny SA, Hillstrom JR, Cole MS, Link BK, Wang SL, Tso JY. The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy. J Immunol 1994; 152: 2385-2392.
24. + T cells can be rapidly activated by a CD3xCD19 bispecific antibody to proliferate and become cytotoxic. Cancer Immunol Immunother 1994; 39: 391-396.
25. Germain RN. MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 1994; 76: 287-299.
26. Fanger MW, Morganelli PM, Guyre PM. Bispecific antibodies. Crit Rev Immunol 1992; 12: 101-124.
27. Vaickus L, Ball ED, Foon KA. Immune markers in hematologic malignancies. Crit Rev Oncol/Hematol 1991; 11: 267-297.
28. Pezzutto A, Dörken B, Rabinovitch PS, Ledbetter JA, Moldenhauer G, Clark EA. CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol 1987; 138: 2793-2799.
29. Bohlen H, Manzke O, Patel B, Moldenhauer G, Dörken B, von Fliedner V, Diehl V, Tesch H. Cytolysis of leukemic B-cells by T-cells activated via two bispecific antibodies. Cancer Res 1993; 53: 4310-4314.
30. Knapp W, Dörken B, Gilks WR, Rieber EP, Schmidt RE, Stein H, von dem Borne AEGK. Leucocyte Typing IV. White Cell Differentiation Antigens. Oxford University Press, Oxford, 1989.
31. Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, Springer T, Tedder TF, Todd RF. Leucocyte Typing V. White Cell Differentiation Antigens. Oxford University Press, Oxford, 1995.
32. Anderson PM, Crist W, Hasz D, Carroll AJ, Myers DE, Uckun FM. G19.4 (aCD3) x B43 (aCD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells. Blood 1992; 80: 2826-2834.
33. Bohlen H, Hopff T, Manzke O, Engert A, Kube A, Wickramanayake PD, Diehl V, Tesch H. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3xCD19 bispecific antibodies in combination with bivalent CD28 antibodies. Blood 1993; 82: 1803-1812.
34. Haagen I-A, Geerars AJ, de Lau WB, Clark MR, van de Griend RJ, Bast BJ, de Gast BC. Killing of autologous B-lineage malignancy using CD3xCD19 bispecific monoclonal antibody in end stage leukemia and lymphoma. Blood 1994; 84: 556-563.
35. Oshimi K, Seto T, Oshimi Y, Masuda M, Okumura K, Mizoguchi H. Increased lysis of patient CD10-positive leukemic cells by T cells coated with anti-CD3 Fab′ antibody cross-linked to anti-CD10 Fab′ antibody. Blood 1991; 77: 1044-1049.
36. +-activated T cells generated from leukemia patients after allogeneic bone marrow transplantation. Bone Marrow Transplant 1995; 15: 193-198.
37. Leung HT, Linsley PS. The CD28 costimulatory pathway. Ther Immunol 1994; 1: 217-228.
38. Guerder S, Carding SR, Flavell RA. B7 costimulation is necessary for the activation of the lytic function in cytotoxic T lymphocyte precursors. J Immunol 1995; 155: 5167-5174.